TORONTO & DALLAS–(BUSINESS WIRE)–$PINK.V #AI–Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced today that it will participate in the following upcoming industry events and conferences:
The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Perimeter’s website at https://ir.perimetermed.com/. When available, webcasts will be posted for replay following the event.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated, investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently under clinical development. The company’s ticker symbol “PINK” refers to the pink ribbons used during Breast Cancer Awareness Month.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts
Shushu Feng
Perimeter Medical Imaging AI, Inc.
Direct: 647-339-7465 (PINK)
Toll-free: 888-988-7465 (PINK)
investors@perimetermed.com
SAN JOSE, Calif., July 6, 2025 /PRNewswire/ -- DentScribe.ai today announced the launch of DentScribe…
This news release does not constitute an offer to sell or a solicitation of an…
NEW YORK, July 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The…
Medsien's Advanced Primary Care Management (APCM) program transforms chronic care with fast deployment, smart automation…
Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…
Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr.…